Greenman M, Bellone S, Demirkiran C, Hartwich TMP, et al. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecol Oncol 2025;199:64-71.
PMID: 40582040